- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06738368
Etoposídeo, prednisona, vincristina, ciclofosfamida e doxorrubicina (DA-EPOCH) com ou sem rituximabe mais Erwinia asparaginase recombinante (JZP458) para o tratamento de leucemia linfoblástica aguda B com Ph negativo recentemente diagnosticada ou leucemia linfoblástica aguda T
Etoposídeo com dose ajustada, prednisona, vincristina, ciclofosfamida e doxorrubicina (DA-EPOCH) ± Rituximabe + Erwinia Asparaginase recombinante (JZP458; Rylaze®) para o tratamento de adultos recém-diagnosticados com linfoma / leucemia linfoblástico agudo negativo para cromossomo Filadélfia
This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Medicamento: Cyclophosphamide
- Medicamento: Prednisone
- Procedimento: Biospecimen Collection
- Biológico: Rituximab
- Procedimento: Computed Tomography
- Procedimento: Positron Emission Tomography
- Biológico: Filgrastim
- Biológico: Pegfilgrastim
- Medicamento: Asparaginase Erwinia chrysanthemi
- Procedimento: Bone Marrow Collection
- Medicamento: Doxorubicin
- Medicamento: Etoposide
- Medicamento: Vincristine
Descrição detalhada
OUTLINE:
Patients receive etoposide intravenously (IV), doxorubicin IV and vincristine IV over 96 hours on days 1-4, cyclophosphamide IV over 1 hour on day 5, prednisone orally (PO) twice daily (BID) on days 1-5 of each cycle. In addition, CD20 positive patients receive rituximab IV on day 1 or 5 of each cycle. Patients also receive JZP458 intramuscularly (IM) once every 2-3 days on days 7-21 for up to 7 doses. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 6, 7, or 8, patients also receive pegfilgrastim subcutaneously (SC) once or filgrastim SC once daily (QD) until absolute neutrophil count (ANC) > 2000/uL past nadir. Patients also undergo blood sample collection and bone marrow collection throughout the study. Additionally, patients with extramedullary disease may undergo computed tomography (CT) or positron emission tomography (PET)/CT throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years then every 6 months for up to 3 years.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults (age 18 years and older) with newly-diagnosed Ph- B-ALL or T-ALL
- In the opinion of the treating investigator, patients must be an unsuitable candidate for a pediatric-inspired regimen, reasons for which may include (but not be limited to) older age (e.g., ≥ 40 years), practical/logistical barriers to or toxicity concerns from administration of a pediatric-inspired regimen
- Marrow or blood involvement by ALL detectable by multi-parameter flow cytometry (MFC)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. (Performance status of 3 will be allowed if poor performance status is thought to be directly secondary to ALL.)
- Total bilirubin ≤ 2.0 x upper limit of normal (ULN) (unless attributed to Gilbert's disease or other causes of inherited indirect hyperbilirubinemia, at which point total bilirubin must be ≤ 4.0 x ULN) (Note: Patients with liver test abnormalities attributable to hepatic involvement by ALL will be permitted if the total bilirubin is ≤ 5.0 x ULN and alanine aminotransferase [ALT]/aspartate aminotransferase [AST] are ≤ 8.0 x ULN.)
- AST (serum glutamic oxaloacetic transaminase [SGOT])/ALT (serum glutamic pyruvic transaminase [SGPT]) ≤ 5.0 x institutional ULN. (Note: Patients with liver test abnormalities attributable to hepatic involvement by ALL will be permitted if the total bilirubin is ≤ 5.0 x ULN and ALT/AST are ≤ 8.0 x ULN.)
- Calculated creatinine clearance of ≥ 60 ml/min/1.73 m^2, as measured by the Modification of Diet in Renal Disease (MDRD) equation, will be eligible
- As patients with ALL frequently have cytopenias, no hematologic parameters will be required for enrollment or to receive the first cycle of treatment. However, adequate recovery of blood counts will be required to receive subsequent cycles
- Ability to give informed consent and comply with the protocol
- Anticipated survival of at least 3 months, independent of ALL
- Female subjects of childbearing potential should use effective non-hormonal contraceptive methods during treatment with JZP458 and for 3 months after the last dose of study drug. Male subjects with female partners of childbearing potential must agree to use an effective method of birth control from the time of signing the consent form until at least 3 months after the last dose of study drug
Exclusion Criteria:
-
Prior systemic therapy for ALL except to control acute symptoms and/or leukocytosis (e.g., corticosteroids, cytarabine, etc.). Cytarabine 500 mg/m^2 per dose up to 2 doses and/or the equivalent of prednisone 50 mg/m^2/day for up to 2 days are permitted
-
Burkitt lymphoma/leukemia
-
Isolated extramedullary or known parenchymal central nervous system (CNS) disease
-
Known hypersensitivity or intolerance to any of the agents under investigation
-
Known history of grade 3+ pancreatitis or chronic pancreatic insufficiency
-
Known active chronic liver disease including, but not limited to, non-alcoholic steatohepatitis, cirrhosis, or non-alcoholic fatty liver disease
-
Other medical or psychiatric conditions that in the opinion of the investigator would preclude safe participation in the protocol
-
Pregnant or nursing
- Pregnancy test is only required in women, unless they are highly unlikely to conceive (defined as [1] surgically sterilized, or [2] postmenopausal [i.e., a woman who is > 50 years old or who has not had menses for ≥ 1 year], or [3] not heterosexually active)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Treatment (DA-EPOCH, rituximab, JZP458)
Patients receive etoposide IV, doxorubicin IV and vincristine IV over 96 hours on days 1-4, cyclophosphamide IV over 1 hour on day 5, prednisone PO BID on days 1-5 of each cycle. In addition, CD20 positive patients receive rituximab IV on day 1 or 5 of each cycle. Patients also receive JZP458 IM every 2-3 days on days 7-21 for up to 7 doses. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 6, 7, or 8, patients also receive pegfilgrastim SC once or filgrastim SC QD until ANC > 2000/uL past nadir. Patients also undergo blood sample collection and bone marrow collection throughout the study. Additionally, patients with extramedullary disease may undergo CT or PET/CT throughout the study. |
Given IV
Outros nomes:
Given PO
Outros nomes:
Undergo blood sample collection
Outros nomes:
Given IV
Outros nomes:
Undergo CT or PET/CT
Outros nomes:
Undergo PET/CT
Outros nomes:
Given SC
Outros nomes:
Given SC
Outros nomes:
Given IM
Outros nomes:
Undergo bone marrow sample collection
Outros nomes:
Given CIV
Outros nomes:
Given CIV
Outros nomes:
Given CIV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Measurable residual disease (MRD) negativity
Prazo: After 4 cycles of treatment (cycle length = 21 days)
|
Will be measured by multi-parameter flow cytometry (MFC). Will be assessed according to the National Comprehensive Cancer Network response criteria. |
After 4 cycles of treatment (cycle length = 21 days)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
MRD negativity
Prazo: After 1 cycle of study therapy (cycle length = 21 days)
|
Will be measured by MFC. Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. |
After 1 cycle of study therapy (cycle length = 21 days)
|
|
Incidence of grade 3 or higher non-hematologic adverse events (AEs)
Prazo: Up to 30 days after last dose of study treatment
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. The incidence of AEs will be reported as ratios or percentages. |
Up to 30 days after last dose of study treatment
|
|
Event-free survival (EFS)
Prazo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict EFS. |
Up to 5 years
|
|
Relapse-free survival (RFS)
Prazo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict RFS. |
Up to 5 years
|
|
Overall survival (OS)
Prazo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict OS. |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ryan D. Cassaday, MD, Fred Hutch/University of Washington Cancer Consortium
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias
- Doenças do sistema imunológico
- Infecções
- Doenças Virais
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Infecções por vírus de DNA
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma Não-Hodgkin
- Linfoma de Células B
- Linfoma
- Leucemia Linfóide
- Leucemia
- Infecções pelo vírus Epstein-Barr
- Infecções Herpesviridae
- Infecções por Vírus Tumorais
- Leucemia-Linfoma Linfoblástico de Células Precursoras
- Doenças hemic e linfáticas
- Linfoma de Burkitt
- Leucemia-Linfoma Linfoblástico Precursor de Células T
- Peptídeos
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Fatores biológicos
- Carboidratos
- Alcalóides
- Podofillotoxina
- Tetra -hidonaftaleno
- Naftalenos
- Hidrocarbonetos aromáticos policíclicos
- Hidrocarbonetos, aromáticos
- Compostos policíclicos
- Glucosídeos
- Glicosídeos
- Hidrolases
- Enzimas
- Enzimas e coenzimas
- Indoles
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Técnicas de química, analíticas
- Análise de espectro
- Mustarazas de fosforamida
- Compostos de mostarda de nitrogênio
- Compostos de mostarda
- Hidrocarbonetos, halogenados
- Fosforamidas
- Compostos organofosforos
- Peptídeos e proteínas de sinalização intercelular
- PregadaDiols
- Amido -hidrolases
- Alcalóides de Vinca
- Alcalóides de triptamina de secologanin
- Alcalóides indol
- Indolizidinas
- Indolizinas
- Antraciclinas
- Nafthacenos
- Aminoglicosídeos
- Glicoproteínas
- Glicoconjugados
- Anticorpos, monoclonais, derivados de murinos
- Daunorubicina
- Fatores estimuladores de colônias
- Fatores de crescimento celular hematopoiético
- Citocinas
- Rituximabe
- Prednisona
- Ciclofosfamida
- Etoposídeo
- Doxorrubicina
- Vincristina
- Asparaginase
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- CT-P10
- Fator estimulador de colônias de granulócitos
- Filgrastim
- Deltacorteno
- prednilideno
- pegfilgrastim
- asparaginase erwinia chrysanthemi recombinante
- fator estimulador de colônias de granulócitos peguilados
Outros números de identificação do estudo
- RG1124788
- NCI-2024-09417 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- FHIRB0020869 (Outro identificador: Fred Hutch/University of Washington Cancer Consortium)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .